References
- Choi B, Kwon S. Seroprevalence comparison of different varicella vaccines among Turkish children. Hum Vaccin Immunother. 2022;18:1–1. doi:10.1080/21645515.2022.2067443.
- What COVID-19 seroprevalence surveys can tell us. Centers of disease control and prevention. CDC [accesed 2022 March 18]. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/seroprevalance-surveys-tell-us.html#::text=CoV%2D2%20antibodies-,Seroprevalence,against%20SARS%2DCoV%2D2.
- Kanra G, Ceyhan M, Ozmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatr Int. 2000;42(6):674–77. doi:10.1046/j.1442-200x.2000.01300.x.
- Umit Z, Sahbudak Bal Z, Zeytinoglu A, Gulbahar Aydogan T, Bag O, Guner Ozenen G, Ozkinay F, Kurugol Z. The comparison of seroconversion rates among different varicella vaccines administered Turkish children; MAV/06 and vOka. Hum Vaccin Immunother. 2021;17(11):4190–93. doi:10.1080/21645515.2021.1967037.